Navigation Links
Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
Date:3/13/2009

NEW YORK, March 13 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually. Applications will be accepted twice a year, with up to $2.5 million in funding available each spring and another $2.5 million available in the fall.

First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinson's research as part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies -- thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson's disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.

Under the 2009 TDI program, MJFF primarily seeks to support pre-clinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical pre-clinical studies necessary for developing, optimizing and evaluating therapeutic strategies that, if successful, can move into human testing.

The first three years of TDI were enthusiastically received by industry researchers. To date the Foundation has awarded nearly $12.8 million total under the initiative for 24 industry-led projects.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded nearly $140 million in research directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gene Network Sciences Announces Michael Gilman as Board Member
2. Nyenrode Honorary Doctorate for Professor Michael E. Porter
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
5. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decades Real Nutritional Heroes
8. Xceleron Names Michael Butler as President & CEO
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):